DCVMN International, Route de Crassier 7, 1262 Nyon, Switzerland.
Clinton Health Access Initiative, 383 Dorchester Ave, Suite 400, Boston, MA 02127, USA.
Vaccine. 2021 Feb 22;39(8):1190-1194. doi: 10.1016/j.vaccine.2020.12.085. Epub 2021 Jan 22.
Development of novel vaccines and improving existing vaccines is critical to addressing areas of unmet or under-addressed health needs globally and to improving existing vaccination coverage and equity. However, vaccine innovation is costly and highly complex. To understand how vaccine manufacturers from developing countries approach innovation, a survey was conducted among company members of the Developing Countries Vaccine Manufacturers Network, in collaboration with the Clinton Health Access Initiative. The survey confirmed that vaccine manufacturers from developing countries are committed to vaccine innovation: 95% of respondents have interest in pursuing vaccine innovation, with strategies targeted towards supplying to low- and middle-income countries. Key barriers to innovation were also surveyed, with respondents highlighting challenges regarding access to in-licensing or joint venture partnerships, financing, and regulatory barriers. Opportunities for innovation are also discussed.
开发新型疫苗和改进现有疫苗对于解决全球未满足或未得到充分解决的健康需求领域以及提高现有疫苗接种覆盖率和公平性至关重要。然而，疫苗创新成本高昂且极其复杂。为了了解发展中国家的疫苗制造商如何进行创新，与克林顿健康倡议组织合作，对发展中国家疫苗制造商网络的公司成员进行了一项调查。调查证实，发展中国家的疫苗制造商致力于疫苗创新：95%的受访者有兴趣从事疫苗创新，其战略目标是向低收入和中等收入国家供应疫苗。调查还对创新的主要障碍进行了调查，受访者强调了在许可或合资伙伴关系、融资和监管障碍方面的挑战。还讨论了创新的机会。
